Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Muenster, Muenster, Germany.
Radiat Oncol. 2019 Apr 15;14(1):63. doi: 10.1186/s13014-019-1265-5.
Patients with plasma-cell neoplasia usually suffer from systemic disease, although a minority (< 5%) may present with solitary involvement of bone or soft tissue (extramedullary plasmacytoma (EMP)). Radiotherapy (RT) is a state-of-the-art treatment for these tumors offering long term curation.
Between January 2005 and January 2017, twenty-seven patients underwent RT at our institution. The aim of this study was to analyse the effectiveness of various RT doses for different forms of EMP.
A total of 33 radiation courses were administered to 27 patients with a median age of 56 years. The median RT dose was 45 Gy (range: 12-55.8). The local control rate was 76% (93% for primary EMP vs. 61% for the secondary EMP lesions; P < 0.05). A complete response (CR) rate to local RT was achieved for 42% lesions (67% for primary EMP vs. 22% for the secondary EMP lesions; P < 0.01). The overall response rate (ORR) for the EMP lesions treated with high-dose regimens (> 45 Gy) versus low-dose regimens (≤ 45 Gy) was 87% versus 67%, respectively (P = 0.2). The median survival with high-dose RT group was significantly longer (P = 0.02). In subgroups analysis, primary EMP patients treated with high-dose RT had a non-significant higher ORR (100% vs. 80%, respectively; P = 0.3,) longer duration of LC (P = 0.3) with a longer survival (P = 0.05) than patients in low-dose group. No significant difference has been detected in secondary EMP patients treated with high-dose RT regarding ORR (60% vs. 62%, respectively; P = 1), and survival (P = 0.4).
RT is an efficacious treatment modality in the treatment of EMP. A radiation dose ≤45 Gy confer a comparable CR rate to high-dose regimens and appears to be an effective treatment for controlling local EMP progression. Radiation dose-escalation may be beneficial for particular subgroups of patients.
浆细胞瘤患者通常患有全身性疾病,尽管少数(<5%)患者可能表现为骨或软组织的单一受累(骨髓外浆细胞瘤(EMP))。放射治疗(RT)是治疗这些肿瘤的一种先进方法,可提供长期缓解。
2005 年 1 月至 2017 年 1 月期间,我们机构对 27 名患者进行了 RT。本研究的目的是分析不同形式的 EMP 中各种 RT 剂量的有效性。
对 27 名患者共进行了 33 次放射治疗,中位年龄为 56 岁。中位 RT 剂量为 45Gy(范围:12-55.8)。局部控制率为 76%(原发性 EMP 为 93%,继发性 EMP 病变为 61%;P<0.05)。局部 RT 达到完全缓解(CR)的病变率为 42%(原发性 EMP 为 67%,继发性 EMP 病变为 22%;P<0.01)。接受高剂量方案(>45Gy)与低剂量方案(≤45Gy)治疗的 EMP 病变的总反应率(ORR)分别为 87%和 67%(P=0.2)。高剂量 RT 组的中位生存期明显延长(P=0.02)。在亚组分析中,接受高剂量 RT 的原发性 EMP 患者的 ORR 虽无显著升高(分别为 100%和 80%;P=0.3),但无显著升高,但局部控制持续时间更长(P=0.3),生存时间更长(P=0.05),低于低剂量组。在接受高剂量 RT 的继发性 EMP 患者中,ORR(分别为 60%和 62%;P=1)和生存(P=0.4)无显著差异。
RT 是治疗 EMP 的有效治疗方法。45Gy 以下的放射剂量与高剂量方案相比具有相似的 CR 率,似乎是控制局部 EMP 进展的有效治疗方法。剂量递增可能对某些特定患者亚组有益。